The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma

JAMA Oncology

Volumn 1, Issue 2, 2015, Pages 168-174

  Sigurdardottir, Elin Edda ^a   Turesson, Ingemar ^b   Lund, Sigrun Helga ^a   Lindqvist, Ebba K ^c   Mailankody, Sham ^d   Korde, Neha ^d   Björkholm, Magnus ^c   Landgren, Ola ^e   Kristinsson, Sigurdur Y ^a,c  

^a UNIVERSITY OF ICELAND   (Iceland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHI SQUARE DISTRIBUTION; COMORBIDITY; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; KAPLAN MEIER METHOD; MALE; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MORTALITY; MULTIPLE MYELOMA; PREDICTIVE VALUE; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; RISK FACTOR; SWEDEN; TIME;

CHI-SQUARE DISTRIBUTION; COMORBIDITY; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TIME FACTORS;

EID: 84965091817     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.23     Document Type: Article

References (26)

1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548.
2. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.Leukemia. 2014;28(5):1122-1128.
3. Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia. 2014;28(6):1346-1348.
4. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25(15):1993-1999.
5. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol. 2010;28(5):830-834.
6. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412-5417.
7. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
8. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-1369.
9. Landgren O, Graubard BI, Katzmann JA, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 2014;28(7):1537-1542.
10. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-569.
11. Kyle RA, Durie BG, Rajkumar SV, et al; International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.Leukemia. 2010;24(6):1121-1127.
12. Turesson I, Kovalchik SA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014;123(3):338-345.
13. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812-817.
14. Bird J, Behrens J, Westin J, et al; Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study Group. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2009;147(1):22-42.
15. Bladé J. Clinical practice. Monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;355(26):2765-2770.
16. Turesson I, Linet MS, Björkholm M, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer. 2007;121(10):2260-2266.
17. Anonymous. Patientregistret 1987-1996: Kvalitet och innehåll. Stockholm, Sweden: EpC, National Board of Health and Welfare; 1998.
18. Axelsson U, Bachmann R, Hällén J. Frequency of pathological proteins (M-components) om 6,995 sera from an adult population. Acta Med Scand. 1966;179(2):235-247.
19. Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.Am J Med. 1978;64(5):814-826.
20. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
21. Therneau T. A Package for Survival Analysis in S. R package version 2.37-2.
22. Bianchi G, Kyle RA, Colby CL, et al. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood. 2010;116(12):2019-2025.
23. Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med.2013;369(5):438-447.
24. Landgren O. Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology. Hematology Am Soc Hematol Educ Program. 2010;2010:295-302.
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
26. Kleber M, Ihorst G, Gross B, et al. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk. 2013; 13(5):541-551.